American pharmaceutical industry officials and trade groups remain cautiously optimistic that intellectual property (IP) negotiations with India can be resolved to the benefit of both nations’ medicine sectors. For now, however, India remains on a so-called ‘priority watch list’ of nations the US is urging to address key IP protection concerns.
The latest congressionally mandated ‘301 Report’, released in April, places India alongside 12 other US trading partner nations, including China, Indonesia, Pakistan and Russia, that ‘present the most significant concerns this year regarding insufficient IP protection or enforcement or actions that otherwise limited market access for persons relying on intellectual property protection’.
India remains on the list for 2015, the report says, but ‘with the full expectation that the new channels for engagement created in the past year will bring about substantive and measurable improvements in India’s intellectual property regime (IPR) for the benefit of a broad range of innovative and creative industries.’
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.